SLS:NASDAQSELLAS Life Sciences Group, Inc. Analysis

SELLAS Life Sciences is trading at $7.99, comfortably above its 20‑day ($6.15), 50‑day ($5.35) and 200‑day ($3.35) simple moving averages, indicating a strong upward momentum. The RSI of 66 and a bullish MACD histogram (+0.22) reinforce the technical strength, while the price sits near the lower end of its 52‑week range with a clear support zone around $4.66 and an upside potential of roughly 25% before hitting the $9.10 resistance. Volume is on an increasing trend and the Fear & Greed Index reads “Extreme Greed” (90.96), suggesting heightened investor optimism despite a high beta of 1.75 and 30‑day volatility exceeding 115%.
Fundamentally, the company remains pre‑revenue with negative earnings, a book‑value multiple of 17.3, and cash burn reflected in operating cash flow of -$28.2M, raising concerns about valuation sustainability. However, recent material news highlights progress in the pivotal Phase 3 REGAL trial for galinpepimut‑S in AML and positive Phase 2 data for SLS009, bolstered by a strategic partnership with Merck, which could unlock significant upside if clinical endpoints are met.